Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 57Uterine Cervical Neoplasms 53Squamous Cell Carcinoma of Head and Neck 52Nasopharyngeal Carcinoma 51Head and Neck Neoplasms 47Stomach Neoplasms 37Parkinson Disease 4, Autosomal Dominant Lewy Body 35Esophageal Neoplasms 31Urinary Bladder Neoplasms 26Small Cell Lung Carcinoma 21Esophageal Squamous Cell Carcinoma 21Ovarian Neoplasms 19Carcinoma 14Neoplasm Metastasis 13Cholangiocarcinoma 13Recurrence 11Neuroblastoma 11Nasopharyngeal Neoplasms 11Carcinoma, Ovarian Epithelial 11Biliary Tract Neoplasms 11Adenocarcinoma Of Esophagus 11Neoplasms 10Gallbladder Neoplasms 10Carcinoma, Transitional Cell 10Testicular Neoplasms 9Adenocarcinoma of Lung 9Teratoma 8Oropharyngeal Neoplasms 8Endometrial Neoplasms 8

Interventions

Cyclophosphamide 24Vincristine 19Doxorubicin 17Radiotherapy 14Prednisone 13Methotrexate 13Cytarabine 13Rituximab 11Dexamethasone 11pegaspargase 10Filgrastim 10Etoposide 10Mercaptopurine 9Calcium Dobesilate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8azathiopurine 8auricularum 8Thioguanine 8Leucovorin 8Radiation 7Daunorubicin 7prednylidene 6deltacortene 6Asparaginase 6blinatumomab 5Prednisolone 5Peripheral Blood Stem Cell Transplantation 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Burkitt Lymphoma × Cisplatin × Clear all
NCT00078949 2023-08-23

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Canadian Cancer Trials Group

Phase 3 Completed
849 enrolled 13 charts
Lymphoid

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡